Galapagos NV (NASDAQ:GLPG) had its price target raised by stock analysts at Stifel Nicolaus from $101.00 to $120.00 in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 19.11% from the company’s current price.

Several other research firms have also recently commented on GLPG. Royal Bank Of Canada assumed coverage on Galapagos NV in a research note on Thursday. They issued a “sector perform” rating and a $98.00 price target on the stock. BidaskClub upgraded Galapagos NV from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. BTIG Research reiterated a “buy” rating and issued a $98.00 price target on shares of Galapagos NV in a research note on Tuesday, June 20th. Nomura boosted their price objective on Galapagos NV from $108.00 to $124.00 and gave the company a “buy” rating in a report on Friday, August 11th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $92.00 price objective on shares of Galapagos NV in a report on Thursday, August 10th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $103.71.

Galapagos NV (NASDAQ GLPG) opened at 100.75 on Friday. The stock has a 50 day moving average price of $101.42 and a 200-day moving average price of $88.32. The stock’s market cap is $5.12 billion. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.54.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at

Institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC bought a new stake in Galapagos NV in the first quarter valued at about $161,000. Bank of Montreal Can increased its holdings in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Galapagos NV in the second quarter valued at about $166,000. New York State Common Retirement Fund bought a new stake in Galapagos NV in the second quarter valued at about $166,000. Finally, Pacad Investment Ltd. bought a new stake in Galapagos NV in the second quarter valued at about $168,000. 23.63% of the stock is owned by hedge funds and other institutional investors.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.